Why the study?
Do glycoprotein IIb/IIIa antagonists improve clinical outcomes in patients with unstable angina for whom PCI is not planned?
Do glycoprotein IIb/IIIa antagonists improve clinical outcomes in patients with unstable angina for whom PCI is not planned?
This systematic review evaluates the clinical and cost-effectiveness of intravenous and oral glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
IV GP IIb/IIIa use yields modest benefits in medically managed unstable angina; challenges routine oral agents while extending cost-effectiveness data.
T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced
No takes yet. Share an insight, caveat, or question.
McDonagh et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: